ArticleTransboundary and emerging diseases2026
Persistent Circulation of Pseudorabies Virus Variants in China: Genomic Features, Pathogenic Characteristics, and Cross-Protective Efficacy of Variant Strain Vaccines.
Article in Transboundary and emerging diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- MEK/ERK-Mediated Transcriptional Repression of Metabolic Genes Confers Host Defense AgainstMicroorganisms · 2026Article
- Persistent Circulation of Pseudorabies Virus Variants in China: Genomic Features, Pathogenic Characteristics, and Cross-Protective Efficacy of Variant Strain Vaccines.Transboundary and emerging diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The continuous circulation of pseudorabies virus (PRV) variants persists in causing substantial economic losses within China's swine industry. Nevertheless, the molecular characteristics and pathogenic potential of the recently emerged variants remain poorly understood, and the cross-protective effectiveness of the newly developed vaccines based on these variants against the circulating strains is still uncertain. In this study, two novel PRV strains, designated WK631 and WK1157, were isolated from clinical samples collected in 2022 and 2024 during investigations of suspected pseudorabies outbreaks. Comparative genomic analysis indicated that both strains share high sequence homology with previously reported PRV variants and harbor sporadic amino acid mutations. Moreover, a small-fragment recombination event was detected in WK631. Pan-genomic alignment has identified genotype-specific molecular signatures: 33 proteins for genotype I, 5 for classical genotype II, and 10 for variant genotype II strains. Subsequently, 14 days after immunization with the PRV variant vaccine, the animals were challenged with WK631, WK1157, or the highly virulent control strain HeN1. Unvaccinated mice exhibited characteristic PRV-induced pruritus and succumbed to infection with 100% mortality within 6 days postchallenge. High viral loads were detected in brain tissues by quantitative PCR and immunohistochemistry, accompanied by typical neuropathological lesions. In contrast, all vaccinated mice survived without exhibiting any clinical symptoms, viral replication, or pathological alterations. This study not only broadens our understanding of the genomic characteristics of PRV variants but also confirms the pathogenic potential of recent isolates and validates the effectiveness of variant-based vaccines, thereby reinforcing their potential use in PRV control strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.